Telo Genomics Corp. (TSXV:TELO)
Canada flag Canada · Delayed Price · Currency is CAD
0.0750
0.00 (0.00%)
Sep 2, 2025, 2:34 PM EDT

Telo Genomics Company Description

Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions primarily in Canada.

Its TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability to identify specific disease mechanisms, predict disease risks, and determine effective treatments.

Its lead product is TeloView-SMM (Smoldering Multiple Myeloma) for SMM patients with high risk of transition to multiple myeloma (MM).

The company also develops TeloView NDMM that predicts newly diagnosed MM patients who may relapse on 1st line therapy; TeloMRD-D Enumaeration that identifies and enumerates MRD cells in post-transplant patients; and TeloViewNG-MRD (Minimal Residual Disease) Profiling for genomic instability profiling of MRD detected cells in post-transplant patients.

It has a collaboration agreement with the Mayo Clinic. Telo Genomics Corp. is headquartered in Toronto, Canada.

Telo Genomics Corp.
Telo Genomics logo
CountryCanada
IndustryDiagnostics & Research
SectorHealthcare
Employees6
CEOSabine Mai

Contact Details

Address:
MaRS Centre
Toronto, M5G 1L7
Canada
Phone416 673 8487
Websitetelodx.com

Stock Details

Ticker SymbolTELO
ExchangeTSX Venture Exchange
Fiscal YearJuly - June
Reporting CurrencyCAD
ISIN NumberCA87975M2085
SIC Code3845

Key Executives

NamePosition
Dr. Sabine Mai Ph.D.Founder, Interim Chief Executive Officer, Chair of the Clinical and Scientific Advisory Board and Director
Guido BaechlerExecutive Chairman
Christopher Ross CPA, CGAChief Financial Officer
Dr. Hans Knecht M.D.Medical laboratory Director and Member of Clinical Advisory Board
Dr. Mark Stene M.B.A., Ph.D.Head of Laboratory Operations